Tempus Q2 revenue $166M, up 25% YoY; guides FY2024 revenue ~$700M

Tempus AI, Inc.

2024-Q2 EPS reported -$9.02 revenue$311,789,000

Revenue $166.0M (+25% YoY); data licensing grew 40% YoY; genomics revenue $112.3M (+22.2%).
Net loss ($552.2M) largely from $493.1M stock compensation and payroll taxes tied to IPO.
Adjusted EBITDA ($31.2M), improved $12.7M QoQ from Q1; Non-GAAP genomics margin 49.4% (+50bps).
FY2024 revenue guidance ~$700M (~32% growth); adjusted EBITDA guided at ~($105M), improvement of ~$50M.
Launched MRD assays, JV with SoftBank for Japan, FDA 510(k) for ECG-AF device, CMS ADLT status for xT CDx.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.